HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing hair-loss ...

Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

Telehealth companies like Hims & Hers (HIMS) are aggressively marketing hair-loss medications to young men, with some patients saying they ...

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated ...

But as the drugstore chain (WBA) prepares to go private and its rival CVS Health Inc. (CVS) experiments with smaller stores, some analysts and researchers see a possible future with even fewer ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

After years of calling obesity drug stocks overhyped, a top analyst now sees Novo Nordisk as a big opportunity.

The second group, so-called "Constrained Losers," are those hard-to-short stocks that have lost the most over the trailing year. The professors found that these stocks also lag the market, but for a ...

Stocks entered a correction on Thursday as the S&P 500 index fell 10% from its recent peak after President Donald Trump escalated the trade war with 200% tariffs on European alcoholic beverages. This ...